Minimal Residual Disease (MRD) testing is a method employed to identify and measure the minute quantity of cancer cells persisting in a patient's body post-treatment. It utilizes advanced techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry to detect remaining disease on a molecular scale.
The clinical significance of MRD testing lies in its ability to track how well treatment is working, forecast the likelihood of disease recurrence, tailor treatments to individual needs, and act as a measure of success in clinical studies. By detecting and addressing MRD, medical professionals aim to enhance treatment effectiveness and boost the chances of patient survival.
As per the BIS Research report, the MRD testing market was valued at $1.47 billion in 2022 and is expected to reach $6.67 billion by 2033, growing at a CAGR of 14.81% between 2023 and 2033.
Several factors are propelling the market for MRD testing forward, notably the broadening of Medicare coverage for MRD testing and the implementation of diagnostics for solid tumors.
Evaluate Free Sample Report: Download Sample Report.
Recently, heightened consumer awareness has led to a surge in the demand for MRD testing. Healthcare providers and researchers have taken note of this shift and are actively working to incorporate MRD testing into clinical routines to fulfill patient expectations.
Market Demand Drivers:
• Advent of MRD Testing and its Awareness among Consumers
• Increasing Incidence of Cancer Cases Demanding MRD Testing
• Expanding Medicare Coverage for MRD Testing
• Rise in Administration of Solid Tumor Diagnosis in MRD Testing Ecosystem
Market Challenges:
• Substantially High Cost of MRD Tests
• Early-Risk of Progression and Relapse due to MRD Negative Result
Market Opportunities:
• Advancements in the Development of Companion Diagnostics
• Rising Number of Clinical Trials in Prolonged MRD-negative Treatment Decisions
The profiled companies were chosen through a combination of expert consultations and an analysis of their market presence, product offerings, and market penetration.
Leading the market are 11 public companies, which together hold about 73.33% of the market share. Meanwhile, four private entities, such as Invivoscribe, Inc. and Mission Bio, among others, make up roughly 26.67% of the market's footprint.
Some prominent names established in this market are:
• Adaptive Biotechnologies
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories, Inc. (Inivata)
• Quest Diagnostics Incorporated
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Sysmex Corporation
• Mission Bio, Inc.
• OPKO Health, Inc. (Genpath)
• Veracyte
• Bio Rad Laboratories, Inc.
• ICON plc (Molecular MD)
• F. Hoffmann-La Roche Ltd
• Invivoscribe, Inc.
• ARUP Laboratories
• Guardant Health, Inc.
To Evaluate Report Coverage: Access Full TOC.
In April 2023, Quest Diagnostics expanded its oncology offerings by purchasing Haystack Oncology, introducing cutting-edge liquid biopsy technology into its portfolio. This strategic move aims to improve personalized cancer treatment through highly sensitive diagnostic tools.
Also in April 2023, Integrated DNA Technologies unveiled the Archer FUSIONPlex Core Solid Tumor Panel, an innovative tool for cancer research that has been upgraded to cover a wider array of single nucleotide variants (SNVs) and indels, enhancing its research capabilities.
In the same month, Adaptive Biotechnologies and Takeda entered a translational research partnership. This collaboration leverages Adaptive's clonoSEQ assay across Takeda's hematologic malignancy treatment lineup, facilitating the assessment of minimal residual disease.
According to the senior Analyst, BIS Research, “The escalating prevalence of various cancers globally, such as leukemia, lymphoma, and solid tumors, has contributed to the growing demand for MRD testing. Healthcare providers and researchers recognize the clinical utility of MRD assessment in monitoring treatment response, predicting relapse, and guiding therapeutic interventions.”
As MRD testing continues to evolve and establish itself as a crucial tool in cancer management, market players must focus on innovation, standardization, and accessibility to capitalize on the lucrative opportunities that lie ahead.
